 PLANEGG, GERMANY ACCESSWIRE July 16, 2021 MorphoSys AG FSE:MOR; NASDAQ:MOR MorphoSys today announced that its Management Board, with the approval of the Supervisory Board, has passed a resolution to increase the share capital of MorphoSys AG by issuing 1,337,552 new ordinary shares from the Authorized Capital 2021-II, excluding pre-emptive rights of existing shareholders, to implement the purchase of 1,337,552 new ordinary shares by Royalty Pharma Investments 2019 ICAV, a subsidiary of Royalty Pharma plc NASDAQ: RPRX Royalty Pharma. The new ordinary shares represent 3.9 of the registered share capital of MorphoSys following the capital increase. 